AMSilk Secures €52M to Unleash Industrial Scale Bio-Silk Revolution
September 15, 2025, 9:34 am
Location: Denmark, Capital Region of Denmark, Gentofte Municipality
Employees: 51-200
Founded date: 1999
AMSilk, a leading innovator in biotech-derived materials, has secured a substantial €52 million in new funding. This significant capital infusion propels the company's ambitious strategy to drastically scale its industrial production of advanced silk-based biomaterials. The investment, led by ATHOS and supported by MIG Capital and Novo Holdings, directly targets increased manufacturing capacity, crucial for meeting surging global demand. These proprietary materials, created by reprogramming microorganisms, offer biodegradable and microplastic-free solutions for diverse sectors like textiles, automotive, and consumer care. This financial backing validates AMSilk's commercial viability and its pivotal role in establishing a new era of high-performance, sustainable materials, accelerating its path to market leadership and cementing its commitment to a circular economy.
AMSilk has achieved a major financial milestone. The company secured €52 million in new funding. This capital injection will dramatically accelerate its industrial production. The goal is to scale its innovative silk-based biomaterials globally.
This substantial investment underscores strong confidence in AMSilk's technology. ATHOS (AT Newtec) led the funding round. Existing investors MIG Capital and Novo Holdings also participated. The financing comprises €30 million in equity and €22 million in convertible bonds. This dual structure provides robust financial flexibility for expansion.
The funding fuels AMSilk’s strategic industrial scale-up. The company aims to boost production capacity significantly. It addresses a rapidly growing global demand. Consumers and industries increasingly seek sustainable material alternatives. AMSilk's biomaterials offer a compelling solution.
AMSilk specializes in advanced biomaterials. These are derived from silk-based proteins. The company uses a patented technology platform. This platform reprograms microorganisms. These reprogrammed organisms then produce the required proteins.
The process transforms man-made proteins into versatile formulations. These include fibers, yarns, hydrogels, and silk powders. These materials possess exceptional performance qualities. They are biodegradable. Crucially, they are free from microplastics. This makes them environmentally superior.
Current applications span numerous industries. Textiles benefit from enhanced strength and sustainability. The automotive sector utilizes lightweight, durable components. Consumer care products gain from biocompatible ingredients. Biomedical uses also show immense promise.
AMSilk has already entered into long-term production agreements. These partnerships are with industrial giants. Evonik and Ajinomoto are key collaborators. These agreements ensure consistent, large-scale output. Dedicated production facilities are now operational. These sites are tailored specifically to AMSilk’s unique technology.
This move to industrial-scale production represents a critical transition. It confirms AMSilk’s commercial viability. It demonstrates the company’s ability to meet high market demand. Investors recognize this potential. They see a clear path to widespread adoption.
The investment bolsters AMSilk's supply chains. It strengthens internal industrial processes. The company is now positioned for full-scale production. This acceleration will bring its innovative materials to a broader global market.
AMSilk's vision extends beyond current applications. The company aims to establish an entirely new industry. This industry will focus on high-performance biotech materials. This move represents a significant step towards a sustainable future. It offers tangible solutions for global environmental challenges.
The demand for such materials is surging. Industries are under pressure to reduce their environmental footprint. Regulations are tightening. Consumer preferences are shifting towards eco-friendly products. AMSilk's offerings align perfectly with these trends.
The company's prior success includes an extension of its Series C financing in 2023. This latest round builds upon that momentum. It signifies continued investor confidence. It also highlights consistent progress in technology and market penetration.
AMSilk plans to build further commercial traction. It will continue forging global collaborations. Partnerships with leading enterprises remain a core strategy. These alliances drive market access and technology adoption. They expand the reach of sustainable biomaterials.
This funding positions AMSilk as a leader. It propels the company within the competitive biotech landscape. Its focus on circular economy principles resonates widely. It offers a tangible alternative to conventional, often polluting, materials.
The impact of AMSilk's technology is far-reaching. It offers sustainable textile solutions, reducing reliance on fossil-fuel-derived synthetics. In automotive, it promises lighter, more sustainable components. For personal care, it means cleaner, safer product ingredients.
The company’s commitment to innovation is clear. Its patented technology platform remains a core asset. This intellectual property protects its unique approach. It ensures continued leadership in the biofabricated materials space.
This funding is more than just capital. It is an endorsement. It is a validation of years of research and development. It confirms the global need for AMSilk's disruptive biomaterials. The journey to a truly sustainable material economy takes a major leap forward with this announcement.
AMSilk has achieved a major financial milestone. The company secured €52 million in new funding. This capital injection will dramatically accelerate its industrial production. The goal is to scale its innovative silk-based biomaterials globally.
This substantial investment underscores strong confidence in AMSilk's technology. ATHOS (AT Newtec) led the funding round. Existing investors MIG Capital and Novo Holdings also participated. The financing comprises €30 million in equity and €22 million in convertible bonds. This dual structure provides robust financial flexibility for expansion.
The funding fuels AMSilk’s strategic industrial scale-up. The company aims to boost production capacity significantly. It addresses a rapidly growing global demand. Consumers and industries increasingly seek sustainable material alternatives. AMSilk's biomaterials offer a compelling solution.
AMSilk specializes in advanced biomaterials. These are derived from silk-based proteins. The company uses a patented technology platform. This platform reprograms microorganisms. These reprogrammed organisms then produce the required proteins.
The process transforms man-made proteins into versatile formulations. These include fibers, yarns, hydrogels, and silk powders. These materials possess exceptional performance qualities. They are biodegradable. Crucially, they are free from microplastics. This makes them environmentally superior.
Current applications span numerous industries. Textiles benefit from enhanced strength and sustainability. The automotive sector utilizes lightweight, durable components. Consumer care products gain from biocompatible ingredients. Biomedical uses also show immense promise.
AMSilk has already entered into long-term production agreements. These partnerships are with industrial giants. Evonik and Ajinomoto are key collaborators. These agreements ensure consistent, large-scale output. Dedicated production facilities are now operational. These sites are tailored specifically to AMSilk’s unique technology.
This move to industrial-scale production represents a critical transition. It confirms AMSilk’s commercial viability. It demonstrates the company’s ability to meet high market demand. Investors recognize this potential. They see a clear path to widespread adoption.
The investment bolsters AMSilk's supply chains. It strengthens internal industrial processes. The company is now positioned for full-scale production. This acceleration will bring its innovative materials to a broader global market.
AMSilk's vision extends beyond current applications. The company aims to establish an entirely new industry. This industry will focus on high-performance biotech materials. This move represents a significant step towards a sustainable future. It offers tangible solutions for global environmental challenges.
The demand for such materials is surging. Industries are under pressure to reduce their environmental footprint. Regulations are tightening. Consumer preferences are shifting towards eco-friendly products. AMSilk's offerings align perfectly with these trends.
The company's prior success includes an extension of its Series C financing in 2023. This latest round builds upon that momentum. It signifies continued investor confidence. It also highlights consistent progress in technology and market penetration.
AMSilk plans to build further commercial traction. It will continue forging global collaborations. Partnerships with leading enterprises remain a core strategy. These alliances drive market access and technology adoption. They expand the reach of sustainable biomaterials.
This funding positions AMSilk as a leader. It propels the company within the competitive biotech landscape. Its focus on circular economy principles resonates widely. It offers a tangible alternative to conventional, often polluting, materials.
The impact of AMSilk's technology is far-reaching. It offers sustainable textile solutions, reducing reliance on fossil-fuel-derived synthetics. In automotive, it promises lighter, more sustainable components. For personal care, it means cleaner, safer product ingredients.
The company’s commitment to innovation is clear. Its patented technology platform remains a core asset. This intellectual property protects its unique approach. It ensures continued leadership in the biofabricated materials space.
This funding is more than just capital. It is an endorsement. It is a validation of years of research and development. It confirms the global need for AMSilk's disruptive biomaterials. The journey to a truly sustainable material economy takes a major leap forward with this announcement.